Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[A management program for primary thrombocytopenia].

H Knutsen1, O Bruserud

  • 1Medisinsk avdeling, Sentralsykehuset i Akershus, Nordbyhagen.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of aggregated exposure to perfluorooctanoic acid (PFOA) from diet and personal care products with concentrations in blood using a PBPK model - Results from the Norwegian biomonitoring study in EuroMix.

Environmental research·2023
Same author

A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Clinical and experimental immunology·2018
Same author

A prospective observational study on effects of fever on red cell transfusion outcome.

Vox sanguinis·2017
Same author

Interleukin 4 (IL4), IL10 and IL13 Inhibit in vitro Cytokine Secretion by Acute Myelogenous Leukemia Blasts in the Presence of Exogenous Hematopoietic Growth Factors.

Hematology (Amsterdam, Netherlands)·2016
Same author

Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34(+) Cells in Multiple Myeloma Patients.

Hematology (Amsterdam, Netherlands)·2016
Same author

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Leukemia·2014
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Correction: Management of acute epistaxis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

More systematic follow-up after childbirth.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Essential thrombocythemia guidelines recommend low-dose aspirin for most patients. Cytoreductive treatment is advised for high-risk individuals, with specific drug choices based on age and complications.

Area of Science:

  • Hematology
  • Oncology

Context:

  • Essential thrombocythemia is a chronic myeloproliferative neoplasm.
  • Characterized by high platelet counts and thromboembolic risk.
  • Most patients are asymptomatic at diagnosis.

Purpose:

  • Present diagnostic and treatment guidelines for essential thrombocythemia.
  • Based on a literature search of international databases and journals.
  • Provide evidence-based recommendations for patient management.

Summary:

  • Low-dose aspirin is recommended for patients with platelet counts < 1,000 x 10(9)/l without bleeding history.
  • Cytoreductive therapy is indicated for disease-related complications or high platelet counts (>1,000-1,500 x 10(9)/l).
  • Hydroxyurea is preferred for patients over 60; anagrelide or interferon-alpha for younger patients, avoiding leukemogens.

Related Experiment Videos

Impact:

  • Aims to optimize management of essential thrombocythemia.
  • Reduce the risk of thromboembolic complications.
  • Improve patient outcomes through evidence-based treatment strategies.